By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Oncology are discussed in a new report. According to news originating from Wuhan, People's Republic of China, by NewsRx correspondents, research stated, "Prodrug development is an important strategy for improving tumor cell targeting and the selectivity of anticancer drugs. In this study, poly(ethylene glycol) and melphalan, an anticancer drug, were linked to the backbone of hyaluronic acid via amide bonds using carbodiimide chemistry to synthesize a poly(ethylene glycol)-hyaluronic acid-melphalan prodrug."
Our news journalists obtained a quote from the research from the Huazhong University of Science and Technology, "The physicochemical properties of the prodrug were characterized by Fourier transform infrared, proton nuclear magnetic resonance, ultraviolet-visible spectroscopy, and dynamic light scattering and transmission electron microscopy. The in vitro drug release profiles and the corresponding in vitro cell evaluation of the prodrug were investigated. The poly(ethylene glycol)-hyaluronic acid-melphalan prodrug was successfully synthesized and self-assembled into 116.4-nm nanoparticles. The release profiles demonstrated that controlled release of the prodrug could be achieved with a sensitive property involving both pH and enzymatic degradation. The poly(ethylene glycol)-hyaluronic acid-melphalan prodrug was more effectively transferred into the ovarian tumor cell (SKOV3) than into human ovarian fibroblast (HOF) cells. It also had a higher inhibition effect on SKOV3 and a lower inhibition effect on HOF than melphalan."
According to the news editors, the research concluded: "This poly(ethylene glycol)-hyaluronic acid-melphalan prodrug, with its controlled release properties and selectivity, is a promising drug delivery system for cancer therapy."
For more information on this research see: Synthesis and characterization of a pH- and enzyme-sensitive poly( ethylene glycol)-hyaluronic acid-melphalan prodrug. Journal of Bioactive and Compatible Polymers, 2013;28(6):527-539. Journal of Bioactive and Compatible Polymers can be contacted at: Sage Publications Ltd, 1 Olivers Yard, 55 City Road, London EC1Y 1SP, England. (Sage Publications - www.sagepub.com/; Journal of Bioactive and Compatible Polymers - jbc.sagepub.com)
The news correspondents report that additional information may be obtained from X. Zhang, Huazhong University of Science & Technology, Coll Pharm, Key Lab Nat Med Chem & Resources Evaluat Hubei Pr, Wuhan 430074, People's Republic of China. Additional authors for this research include H.X. Xu, Z. Newaz, Y. Zhang, M. Liu, Z.J. Huang, H. Liu, X.Q. Niu, J.P. Wang and P.H. Xu (see also Oncology).
Keywords for this news article include: Asia, Wuhan, Alkenes, Oncology, Ethylene Glycols, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC